Tyra Biosciences, Inc. is a preclinical-stage biopharmaceutical company headquartered in Carlsbad, California, dedicated to the development of innovative targeted therapies that address tumor resistance mechanisms in oncology. Through its proprietary drug discovery platform, the company seeks to enhance therapeutic efficacy and improve patient outcomes for those facing complex resistance challenges. With a strategic focus on novel therapeutics, Tyra aims to establish itself as a pivotal player in the dynamic cancer treatment landscape, positioning itself to offer transformative solutions for patients in need. Show more

Location: 2656 STATE STREET, CARLSBAD, CA, UNITED STATES, 92008, Carlsbad, CA, 92008, USA | Website: https://tyra.bio | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

1.645B

52 Wk Range

$6.42 - $32.44

Previous Close

$30.82

Open

$30.65

Volume

560,552

Day Range

$30.36 - $31.43

Enterprise Value

1.376B

Cash

61.95M

Avg Qtr Burn

-22.38M

Insider Ownership

3.16%

Institutional Own.

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TYRA-300 Details Pediatric Achondroplasia	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TYRA-300 Details Low-grade, intermediate risk non-muscle invasive bladder cancer (IR NMIBC)	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Dabogratinib (TYRA-300) (FGFR3 Inhibitor) Details Low-Grade Upper Tract Urothelial Carcinoma	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TYRA-300 Details Cancer, Solid tumor/s	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TYRA-430 Details Cancer, Hepatocellular carcinoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TYRA-200 Details Intrahepatic cholangiocarcinoma , Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.